Health Care • Medical/Dental Instruments
$68.10 ▼ -3.08
(-4.33%)
MKT CAP: $2.06B • VOL: 796.4K
52W L $39 52W H $147
INSP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $912.0M | $802.8M | $624.8M |
| YoY Revenue Growth % | +13.6% | +28.5% | — |
| Gross Profit | $778.8M | $679.8M | — |
| Gross Margin % | 85.4% | 84.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $51.0M | $36.1M | -$40.3M |
| Operating Margin % | 5.6% | 4.5% | -6.4% |
| Net Income (GAAP) | $145.4M | $53.5M | -$21.2M |
| EBITDA (Normalized) | $81.8M | $67.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $117.0M | $130.2M | $24.7M |
| Capital Expenditures (CapEx) | $38.5M | $39.1M | — |
| Free Cash Flow (FCF) | $78.5M | $91.1M | $24.7M |
| FCF Margin % | 8.6% | 11.4% | 3.9% |
| Return on Invested Capital (ROIC %) | 6.0% | 5.3% | — |
| Cash & Short-Term Equivalents | $104.8M | $150.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $781.2M | $689.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INSP.